The Antiinflammatory Effects of Aprotinin in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass

A. Stammers, S. Huffman, A. Alonso, L. Fristoe, G. Hill, Dana Casebeer, R. P. Diego, Zuorui Song
{"title":"The Antiinflammatory Effects of Aprotinin in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass","authors":"A. Stammers, S. Huffman, A. Alonso, L. Fristoe, G. Hill, Dana Casebeer, R. P. Diego, Zuorui Song","doi":"10.1051/ject/1997293114","DOIUrl":null,"url":null,"abstract":"Aprotinin has been shown to effectively attenuate cardiopulmonary bypass (CPB) induced coagulopathies. Because aprotinin is a serine protease inhibitor, it may exert additional properties that reduce the risks associated with extracorporeal flow. The purpose of this study was to prospectively evaluate the antiinflammatory effects of aprotinin with specific emphasis on pulmonary function.\nAfter Institutional Review Board approval, 20 patients undergoing first time coronary artery bypass grafting were randomly assigned to receive either a full dose regimen of aprotinin (APR, n=8), or volumetric equal control (CTR, n= 12). Biological markers of inflammation and coagulation were measured at 3 time periods: immediately prior to drug administration, at chest closure, and at 24 hours post cardiotomy, and included total complement, polymorphonuclear neutrophil (PMN) elastase, Factor XII, protein C, protein S, fibrin split products (FSP), D-dimers. Pulmonary function was assessed throughout intensive care unit (ICU) stay.\nThere were no differences observed between groups in either preoperative, surgical, anesthesia or perfusion parameters. Twenty-four hour chest tube drainage in the APR group was significantly less than that observed in CTR patients (435.1±169.6 vs. 944.0±585.1, p<.02). Patients receiving aprotinin received significantly lower transfusions of red blood cells, platelets, and fresh frozen plasma. Upon entry into the ICU the CTR group had significantly higher mean airway pressures (8.3±1.5 vs. 10.8±2.9 em H2O, p<.03), higher PaCO2 levels (37.1±4.8 vs. 43.3±7.1 mmHg, p<.04), and higher FIO2 settings (0.63±0.18 vs. 0.75±0.20, p=.l6). Postoperative FSP and D-dimers were significantly lower in the APR treated patients.\nIn conclusion, the use of aprotinin resulted in significant improvements to postoperative patient outcomes as assessed by transfusion requirements, blood loss, coagulation markers and pulmonary function.","PeriodicalId":309024,"journal":{"name":"The Journal of ExtraCorporeal Technology","volume":"28 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1997-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"12","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of ExtraCorporeal Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1051/ject/1997293114","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 12

Abstract

Aprotinin has been shown to effectively attenuate cardiopulmonary bypass (CPB) induced coagulopathies. Because aprotinin is a serine protease inhibitor, it may exert additional properties that reduce the risks associated with extracorporeal flow. The purpose of this study was to prospectively evaluate the antiinflammatory effects of aprotinin with specific emphasis on pulmonary function. After Institutional Review Board approval, 20 patients undergoing first time coronary artery bypass grafting were randomly assigned to receive either a full dose regimen of aprotinin (APR, n=8), or volumetric equal control (CTR, n= 12). Biological markers of inflammation and coagulation were measured at 3 time periods: immediately prior to drug administration, at chest closure, and at 24 hours post cardiotomy, and included total complement, polymorphonuclear neutrophil (PMN) elastase, Factor XII, protein C, protein S, fibrin split products (FSP), D-dimers. Pulmonary function was assessed throughout intensive care unit (ICU) stay. There were no differences observed between groups in either preoperative, surgical, anesthesia or perfusion parameters. Twenty-four hour chest tube drainage in the APR group was significantly less than that observed in CTR patients (435.1±169.6 vs. 944.0±585.1, p<.02). Patients receiving aprotinin received significantly lower transfusions of red blood cells, platelets, and fresh frozen plasma. Upon entry into the ICU the CTR group had significantly higher mean airway pressures (8.3±1.5 vs. 10.8±2.9 em H2O, p<.03), higher PaCO2 levels (37.1±4.8 vs. 43.3±7.1 mmHg, p<.04), and higher FIO2 settings (0.63±0.18 vs. 0.75±0.20, p=.l6). Postoperative FSP and D-dimers were significantly lower in the APR treated patients. In conclusion, the use of aprotinin resulted in significant improvements to postoperative patient outcomes as assessed by transfusion requirements, blood loss, coagulation markers and pulmonary function.
抑酶蛋白在心脏手术合并体外循环患者中的抗炎作用
抑酶蛋白已被证明可以有效地减弱体外循环(CPB)诱导的凝血功能障碍。因为抑肽蛋白是一种丝氨酸蛋白酶抑制剂,它可以发挥额外的特性,降低与体外血流相关的风险。本研究的目的是前瞻性评估抑酶蛋白的抗炎作用,并特别强调肺功能。经机构审查委员会批准后,20例首次行冠状动脉旁路移植术的患者被随机分配接受全剂量的抗肽蛋白治疗(APR, n=8),或容量相等的对照组(CTR, n= 12)。在给药前、闭胸时和开心术后24小时3个时段测量炎症和凝血生物学标志物,包括总补体、多形核中性粒细胞(PMN)弹性酶、因子XII、蛋白C、蛋白S、纤维蛋白分裂产物(FSP)、d -二聚体。在重症监护病房(ICU)住院期间评估肺功能。两组术前、手术、麻醉或灌注参数均无差异。APR组24小时胸管引流明显少于CTR组(435.1±169.6比944.0±585.1,p< 0.02)。接受抑酶蛋白治疗的患者红细胞、血小板和新鲜冷冻血浆的输注量显著降低。进入ICU时,CTR组的平均气道压力(8.3±1.5比10.8±2.9 em H2O, p< 0.03)、PaCO2水平(37.1±4.8比43.3±7.1 mmHg, p< 0.04)和FIO2水平(0.63±0.18比0.75±0.20,p= 0.16)显著升高。APR治疗患者术后FSP和d -二聚体明显降低。总之,通过输血需求、失血量、凝血指标和肺功能评估,抑肽蛋白的使用显著改善了术后患者的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信